EFS and OS in R-CHOP-treated DLBCL patients whose tumors were stratified according to the number of adverse features in immunohistochemical stainings for MYChigh, BCL2high, and BCL6low. (A, B) Survival curves of patients stratified according to the presence of 0, 1, 2, or 3 adverse features. (C, D) Survival curves of patients who were stratified according to the presence of 0 or 1 and >1 adverse features. (E, F) Survival curves of patients stratified according to the presence of 0 or 1 and >1 adverse features and IPI groups 1,2 and 3-5. The numbers of patients within the respective groups and P values are indicated.